Domestic companies are one step closer to commercializing DPP-4 inhibitor and SGLT-2 inhibitor combination therapies in Korea.

Until now, there were only imported DPP-4+SGLT-2 inhibitor combination therapies available, but Korean pharmaceutical companies have now started to target the market with new developments.

According to industry sources on the 7th, Dongkoo Bio&Pharma recently submitted an application to the Ministry of Food and Drug Safety for the approval of its PP-4 inhibitor with SLGT-2 inhibitor combination "Citaflojin Tab.."

The submission is also stated in the company’s business report that was recently uploaded on the electronic disclosure system.